ANVS revenueQ2 2026$0
ANVS revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Annovis Bio Inc. (ANVS) financials
For the twelve months ended Jun 30, 2026, Annovis Bio Inc. reported $0 of revenue and -$49.52M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$49.52M
- Cash
- $18.73M
- Market cap
- $38.6M
FY2019FY2025
FY2019FY2025
ANVS revenue and earnings growth
ANVS net incomeQ2 2026-$14.82M
ANVS net income was -$14.82M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.22M a year earlier. For the full fiscal 2025 it was -$28.85M, compared with -$24.59M in fiscal 2024.
ANVS EPSQ2 2026-$0.40
ANVS diluted EPS was -$0.40 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.40.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $25.22M | $20.00M | $38.79M | $16.52M | $8.48M | $3.05M | $776.3K |
| Selling, general and admin | $4.48M | $6.70M | $6.24M | $9.00M | $6.06M | $3.59M | $829.4K |
| Operating income | -$29.70M | -$26.69M | -$45.04M | -$25.51M | -$14.54M | -$6.64M | -$1.61M |
| Pre-tax income | - | - | -$56.20M | -$25.33M | -$14.49M | -$5.46M | -$991.0K |
| Income tax | $0 | - | - | - | - | - | $0 |
| Net income | -$28.85M | -$24.59M | -$56.20M | -$25.33M | -$14.49M | -$5.46M | -$991.0K |
| EPS, basic | -$1.40 | -$2.02 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | -$3.51 |
| EPS, diluted | -$1.40 | -$2.31 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | -$3.51 |
| Diluted shares | 20.6M | 12.2M | 9.0M | 8.2M | 7.6M | 6.3M | 282,614 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.53M | $10.55M | $5.75M | $28.38M | $45.69M | $8.07M | $1.9K |
| Current assets | - | - | $10.21M | $36.02M | $46.00M | $8.12M | $747.5K |
| Total assets | $21.08M | $13.93M | $10.21M | $36.02M | $46.00M | $8.12M | $1.12M |
| Current liabilities | $3.64M | $3.88M | $4.28M | $7.70M | $1.51M | $578.4K | $2.01M |
| Long-term debt | - | - | - | - | - | - | $499.8K |
| Total debt | - | - | - | - | - | - | $499.8K |
| Total liabilities | $4.23M | $4.62M | $17.96M | $7.70M | $1.51M | $578.4K | $2.62M |
| Shareholders' equity | $16.85M | $9.31M | -$7.75M | $28.32M | $44.49M | $7.54M | -$8.58M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.62M | -$21.89M | -$39.97M | -$17.31M | -$9.13M | -$3.97M | -$476.5K |
| Financing cash flow | $34.60M | $26.69M | $17.34M | $4.6K | $46.74M | $12.04M | $443.1K |
| Stock-based compensation | $1.80M | $3.84M | $4.63M | $9.15M | $4.70M | $1.86M | $8.5K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $12.01M | $16.72M | $8.75M | $6.29M | $5.16M | $5.01M | $5.00M | $2.69M | $5.79M | $6.51M | $8.90M | $13.84M |
| Selling, general and admin | $2.37M | $1.29M | $955.2K | $1.14M | $1.11M | $1.27M | $1.74M | $1.70M | $1.98M | $1.29M | $1.54M | $1.03M |
| Operating income | -$14.38M | -$18.01M | -$9.71M | -$7.43M | -$6.27M | -$6.28M | -$6.73M | -$4.39M | -$7.76M | -$7.81M | -$10.44M | -$14.86M |
| Pre-tax income | - | - | - | - | - | - | - | -$12.64M | -$5.02M | -$1.07M | -$22.21M | -$14.72M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | - | $0 | $0 | $0 | - | $0 |
| Net income | -$14.82M | -$17.61M | -$9.83M | -$7.26M | -$6.22M | -$5.54M | -$5.86M | -$12.64M | -$5.02M | -$1.07M | -$22.21M | -$14.72M |
| EPS, basic | -$0.40 | -$0.63 | - | -$0.37 | -$0.32 | -$0.32 | -$0.51 | -$0.97 | -$0.44 | -$0.10 | -$2.34 | -$1.63 |
| EPS, diluted | -$0.40 | -$0.63 | - | -$0.37 | -$0.32 | -$0.32 | -$0.18 | -$0.97 | -$0.44 | -$0.72 | -$2.46 | -$1.63 |
| Diluted shares | 37.5M | 27.8M | - | 19.7M | 19.5M | 17.4M | - | 13.0M | 11.3M | 10.8M | - | 9.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $18.73M | $14.22M | $19.53M | $15.29M | $17.13M | $22.24M | $10.55M | $12.64M | $4.00M | $3.14M | $5.75M | $6.35M |
| Current assets | - | - | - | - | - | - | - | - | - | $7.81M | $10.21M | $10.22M |
| Total assets | $22.04M | $16.24M | $21.08M | $17.19M | $21.45M | $26.74M | $13.93M | $14.36M | $5.05M | $7.81M | $10.21M | $10.22M |
| Current liabilities | $6.36M | $12.79M | $3.64M | $3.73M | $2.81M | $2.50M | $3.88M | $5.39M | $4.06M | $4.87M | $4.28M | $3.56M |
| Total liabilities | $26.29M | $13.12M | $4.23M | $4.03M | $3.12M | $2.68M | $4.62M | $7.30M | $6.80M | $11.17M | $17.96M | $3.56M |
| Shareholders' equity | -$4.25M | $3.13M | $16.85M | $13.16M | $18.33M | $24.05M | $9.31M | $7.06M | -$1.75M | -$3.35M | -$7.75M | $6.66M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.91M | -$9.01M | -$8.93M | -$3.49M | -$5.11M | -$8.10M | -$8.29M | -$3.20M | -$3.38M | -$7.03M | -$9.36M | -$9.37M |
| Financing cash flow | $26.42M | $3.70M | $13.17M | $1.64M | $0 | $19.78M | $6.20M | $11.84M | $4.24M | $4.42M | $8.76M | $0 |
| Stock-based compensation | $1.61M | $182.8K | $356.5K | $444.6K | $496.6K | $499.9K | $1.48M | $393.1K | $1.60M | $364.8K | $882.4K | $632.2K |
Key ratios
Source: XBRL data Annovis Bio Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ANVS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ANVS | $0 | - | -$49.52M | - | $38.6M |
| AVXL | - | - | -$13.02M | - | $113.1M |
| ABOS | - | - | -$103.96M | - | $17.6M |
| PRTA | $52.73M | +347.4% | -$23.96M | -45.4% | $450.9M |
| CGTX | - | - | -$15.99M | - | $65.3M |
ANVS FAQ
5 questionsWhat is ANVS revenue?
Annovis Bio Inc. (ANVS) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $0.Is ANVS profitable?
No. Annovis Bio Inc. reported a net loss of $49.52M for the twelve months ended Jun 30, 2026.How much cash and debt does ANVS have?
Annovis Bio Inc. reported $18.73M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did ANVS last report financial results?
The latest statements here come from Annovis Bio Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this ANVS financial data come from?
Quantisnow builds these statements from the structured XBRL data Annovis Bio Inc. files with the SEC. It is provided for information only and is not investment advice.